Glaxo invests $120M into new manufacturing hub

GlaxoSmithKline, a British drugmaker, is investing $120 million to expand its manufacturing facility in Upper Merion, Pa., according to BioPharma-Reporter.com.

The manufacturing facility will house both the research and development and manufacturing teams.

The facility will focus its production efforts on the company's pipeline of biologic medicines, including gene therapies and vaccines. Glaxo hopes having the teams under one roof will speed the production of new medicines.

The expansion is part of a larger $400 million project to expand its manufacturing capabilities in vaccines and specialty medicines, according to BioPharma-Reporter.com.

Read the full article here.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars